Kinarus Therapeutics Holding AG
SIX:KNRS
Intrinsic Value
Perfect Holding SA engages in the provision of aviation services. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of KNRS.
Kinarus Therapeutics Holding AG's market capitalization is 11.7B CHF.
KNRS stock price is 9 CHF.
KNRS.
KNRS. Open DCF Valuation
KNRS. Open Relative Valuation
KNRS.
KNRS has negative Free Cash Flow for the last twelve months.
KNRS has negative Net Income for the last twelve months.
KNRS has negative Operating Income for the last twelve months.
KNRS's ROE (Return on Equity) for the past 12 months is negative and is equal to -237%.
KNRS's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -248%.
KNRS's long-term liabilties (274k CHF) exceed its long-term assets (111k CHF).
KNRS's short-term liabilties (275k CHF) exceed its short-term assets (111k CHF).
KNRS has negative three-year average ROE (Return on Equity): -185%. The company is not efficient at transforming stockholders' equity into net income.
KNRS has very high three-year average ROIC (Return on Invested Capital): 623%. The company is very efficient at using invested capital to generate operating income.
KNRS's D/E (Debt to Equity) is very low and is equal to 0.
KNRS's Altman Z-Score is very low and is equal to -405.79.
Fundamental Analysis
Kinarus Therapeutics Holding AG
Balance Sheet Decomposition
Kinarus Therapeutics Holding AG
| Current Assets | 111k |
| Receivables | 108k |
| Other Current Assets | 3k |
| Current Liabilities | 275k |
| Accounts Payable | 56k |
| Accrued Liabilities | 86k |
| Other Current Liabilities | 133k |
| Non-Current Liabilities | -1k |
| Other Non-Current Liabilities | -1k |
Earnings Waterfall
Kinarus Therapeutics Holding AG
|
Revenue
|
0
CHF
|
|
Operating Expenses
|
-13.9m
CHF
|
|
Operating Income
|
-13.9m
CHF
|
|
Other Expenses
|
-6k
CHF
|
|
Net Income
|
-13.9m
CHF
|
Free Cash Flow Analysis
Kinarus Therapeutics Holding AG
KNRS Profitability Score
Profitability Due Diligence
Kinarus Therapeutics Holding AG's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Kinarus Therapeutics Holding AG's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
KNRS Solvency Score
Solvency Due Diligence
Kinarus Therapeutics Holding AG's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Kinarus Therapeutics Holding AG's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KNRS Price Targets Summary
Kinarus Therapeutics Holding AG
Shareholder Return
KNRS Price
Kinarus Therapeutics Holding AG
| Average Annual Return | 82.2% |
| Standard Deviation of Annual Returns | 235.33% |
| Max Drawdown | -100% |
| Market Capitalization | 11.7B CHF |
| Shares Outstanding | 1 299 619 968 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Kinarus Therapeutics Holding AG
Country
Industry
Market Cap
Dividend Yield
Description
Perfect Holding SA engages in the provision of aviation services. The company is headquartered in Basel, Basel-Stadt. The firm conducts its work within clinical-stage area and its activities include discovery, examination and development of medicines that are intended for the treatment of viral, respiratory, and ophthalmic diseases. Kinraus therapeutic drug is patent protected KIN001 which is a combination of pamapimod and pioglitazone. KIN0001 offers oral, long-term treatment of diseases with severe impact on the comfort of living.
You don't have any saved screeners yet
